NEW YORK, June 15, 2023 – CureDuchenne, Muscular Dystrophy Association (MDA), and Parent Project Muscular Dystrophy (PPMD), today announced a collaborative clinical trial grant to test repurposing of the FDA-approved […]
Tickets and Sponsorships Available in Support of Nonprofit Dedicated to Finding and Funding Cure for Duchenne Muscular Dystrophy Knoxville, TN. (June 5, 2023) – Knoxville Brewfest, the city’s most anticipated […]
“CureDuchenne is a leader in funding pioneering research aimed at advancing the best possible therapies for DMD patients, and we value their vote of confidence and financial support of our snRNA-mediated exon skipping platform,” said Jim Burns, Ph.D., Locanabio’s chief executive officer.
My name is Debra Miller, founder and CEO of CureDuchenne, and the mother of an incredible son, Hawken, who has Duchenne muscular dystrophy. I’m here today to represent the voice of patient advocacy organizations serving those impacted by Duchenne – all of whom are in support of the accelerated approval of SRP-9001.
Newport Beach, Calif. (May 11, 2023) – CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). […]
CureDuchenne Ventures announces an investment in Insmed Inc. to support the development of INS1201, their next generation intracerebroventricular (ICV) delivered AAV to directly address limitations of current gene therapy approaches.
CureDuchenne’s Second Annual “Napa in Miami” Wine Tasting and Auction Raises More Than $1.2 Million to Help Find a Cure for Duchenne Muscular Dystrophy
CureDuchenne and PicnicHealth Announce Real-World Evidence-Focused Partnership to Incorporate Participant Medical Records into CureDuchenne Link
CureDuchenne’s Second Annual “Napa in Miami” Wine Tasting and Auction Raises More Than $1.2 Million to Help Find a Cure for Duchenne Muscular Dystrophy